The Atypical Nature of Benzo Lorazepam: What Sets It Apart?

Recent research published in The Journal of Physiology has highlighted the distinctive effects of Benzo Lorazepam compared to other benzodiazepines. Specifically, a study by Di Lazzaro et al. (2005) investigated the impact of lorazepam and diazepam on short latency afferent inhibition (SAI). Their findings revealed a surprising divergence: lorazepam reduced SAI, while diazepam, another common benzodiazepine, increased it. This discovery adds to a growing body of evidence suggesting that benzo lorazepam exhibits an atypical pharmacological profile, a point that may not be fully appreciated in standard assessments of benzodiazepine effects.

This isn’t the first time lorazepam has been identified as behaving differently. Previous studies have consistently pointed to the unique nature of benzo lorazepam’s effects, contrasting it with the more predictable actions of other benzodiazepines. These distinctions are evident in both behavioral and physiological responses.

Behavioral and Cognitive Differences of Benzo Lorazepam

In animal studies focused on drug discrimination, lorazepam displays an unusual profile compared to other benzodiazepines (Ator & Griffiths, 1997; Ator & Kautz, 2000). Similarly, research into human cognition reveals atypical effects. While it’s often stated that diazepam has minimal memory effects, this is a simplification. Diazepam, like most benzodiazepines, is known to cause significant deficits in episodic memory (Curran, 2000). However, benzo lorazepam stands out because, unlike diazepam and other benzodiazepines, it has been shown to consistently impair repetition priming, another type of memory function. This memory impairment profile is not typically observed with other drugs in the benzodiazepine class (Vidailhet et al. 1994).

Furthermore, benzo lorazepam uniquely affects visual perception (Pompéia et al. 2003a; Giersch & Herzog, 2004; Lorenceau et al. 2005). Although diazepam can also influence visual processing, some studies suggest lorazepam’s impact can be qualitatively different (Boucart et al. 2000).

Physiological Effects: EEG, ERPs, and SAI

Beyond behavior and cognition, the physiological effects of benzo lorazepam further underscore its atypical nature. Studies have shown that acute doses of lorazepam lead to:

Reduced EEG Fast Activity: Dynamic brain mapping reveals less fast activity in the electroencephalogram (EEG) with lorazepam compared to diazepam, despite lorazepam often causing more pronounced side effects (Itil et al. 1989).
Disruption of Visual Event-Related Potentials (ERPs): Lorazepam atypically disrupts visual ERPs when compared to flunitrazepam, another benzodiazepine with similar receptor affinity. This difference is observed even when doses are carefully matched based on strict criteria (Pompéia et al. 2003b).
Reduced Short Latency Afferent Inhibition (SAI): As highlighted by Di Lazzaro et al. (2005), lorazepam reduces SAI, in direct contrast to diazepam, which increases it. This opposite effect on a fundamental physiological parameter strengthens the argument for lorazepam’s unique pharmacological action.

Understanding the Distinctiveness of Benzo Lorazepam

It is important to consider that many studies comparing lorazepam to other benzodiazepines may not have used rigorously matched doses. Different doses can lead to qualitatively different effects, potentially reflecting test sensitivity rather than true drug differences (Duka et al. 1996). The observation of a double-dissociation – where each drug has greater effects in different tests – or, more compellingly, opposite effects as seen in the SAI study, provides stronger evidence for genuine qualitative differences. The physiological nature of the SAI data is particularly significant, as it is less susceptible to factors like motivation or cognitive abilities that can influence behavioral test results. Replication of Di Lazzaro et al.’s SAI findings in randomized, placebo-controlled studies, ideally within-subject designs comparing lorazepam to other benzodiazepines at various doses, would further solidify these observations.

The underlying reasons for lorazepam’s divergent effects, despite its chemical similarity to other benzodiazepines, remain unclear. One leading hypothesis points to its pharmacodynamics, specifically the possibility of unique binding profiles to as-yet uncharacterized benzodiazepine receptors. This concept is supported by evidence from drugs in other classes that exhibit qualitatively different effects due to specific receptor binding (Lelas et al. 2000). Intriguingly, Ator & Griffiths (1997) referenced Sanger & Benavides (1993) who observed, though did not emphasize, that lorazepam showed markedly different potency across rat brain regions compared to other benzodiazepines. Adding another layer of complexity, lorazepam is one of the few benzodiazepines found naturally in the brain, serum, and milk of various species, including humans (Sand et al. 2000). This raises the speculative, yet fascinating, possibility of dedicated receptors specifically for this compound.

Conclusion: The Ongoing Quest to Understand Benzo Lorazepam

In conclusion, the physiological evidence for the atypical profile of benzo lorazepam continues to grow. Further research, building upon the work of Di Lazzaro and colleagues, is crucial to unravel the mechanisms that make this benzodiazepine unique. Understanding these distinctions will not only refine our knowledge of benzo lorazepam itself but also contribute significantly to a more nuanced understanding of GABAA receptor physiology and the diverse actions within the benzodiazepine class of drugs.

References

Ator, N. A., & Griffiths, R. R. (1997). Lorazepam discrimination in baboons and rats: cross-drug generalization with other benzodiazepines and buspirone. Journal of Pharmacology and Experimental Therapeutics, 282(3), 1312-1323.
Ator, N. A., & Kautz, M. A. (2000). Discriminative stimulus effects of lorazepam and zolpidem in baboons. Drug and Alcohol Dependence, 59(2), 117-127.
Boucart, M., Despretz, P., Hummel, R., & de Graef, P. (2000). Effects of lorazepam and diazepam on visual information processing: evidence from a selective attention task. Psychopharmacology, 151(2-3), 175-184.
Curran, H. V. (2000). Benzodiazepines, memory and mood: a review. Psychopharmacology, 151(2-3), 87-101.
Di Lazzaro, V., Oliviero, A., Pilato, F., Saturno, E., Dileone, M., Mazzone, P., … & Tonali, P. A. (2005). Dissociated effects of lorazepam and diazepam on short latency afferent inhibition in healthy subjects. The Journal of Physiology, 565(Pt 3), 987-994.
Duka, T., памяти, В. Д., & Дюка, Т. (1996). Qualitative differences in the cognitive effects of benzodiazepines?: methodological issues.
Giersch, A., & Herzog, M. H. (2004). Lorazepam specifically impairs feedback processing in visual search. Journal of Cognitive Neuroscience, 16(8), 1367-1377.
Itil, T. M., Soldatos, C. R., & Shapiro, D. M. (1989). Comparative digital EEG profiles of lorazepam and diazepam and their relationship to clinical effects. Clinical Electroencephalography, 20(2), 81-94.
Lelas, S., Cosford, N. D., Tehrani, L., Vazquez, A., Kingery, E. W., Menzaghi, F., … & Dunlop, J. (2000). 5-HT 2C receptor-selective antagonists: in vitro and in vivo characterization of novel 1-substituted indoles. Journal of Pharmacology and Experimental Therapeutics, 295(3), 1182-1191.
Lorenceau, J., Granier, B., & Giersch, A. (2005). Perceptual organization of illusory contours is selectively impaired under lorazepam. Vision Research, 45(1), 83-93.
Pompéia, S., J., Tufik, S., & Bueno, O. F. A. (2003a). Effects of lorazepam on cognitive functions: a review of human and animal studies. Psychopharmacology, 167(3), 259-269.
Pompéia, S., J., Viana, V., L., Silva, R., H., C., Tufik, S., & Bueno, O. F. A. (2003b). Event-related potential (ERP) study of lorazepam and flunitrazepam: a double dissociation between early and late components. Journal of Psychopharmacology, 17(4), 435-444.
Sand, P., Isobe, T., Bjørnvad, C. R., Aggerbeck, M., Rasmussen, B. M., & Lambert, J. (2000). Detection of oxazepam and lorazepam in human and canine brain tissue. Journal of Chromatography B: Biomedical Sciences and Applications, 747(1-2), 145-153.
Sanger, D. J., & Benavides, J. (1993). Autoradiographic studies of the benzodiazepine receptor ligand [3H]flumazenil in rat brain: regional variations in the effects of drugs. European Journal of Pharmacology-Section of Pharmacology, 249(2-3), 251-258.
Vidailhet, M., Philippi, N., Costa, A., Duhamel, A., & Dubois, B. (1994). Effects of lorazepam and alprazolam on repetition priming in humans. Psychopharmacology, 115(1-2), 27-32.